ONLY ANDEMBRY offers once-monthly dosing from the start for all patients with no reports of injection-site pain1*

* In the VANGUARD pivotal phase 3 trial.

Simple Administration

  • Monthly dosing from Day 1 for all patients 12 years and older
  • Subcutaneous self-injection delivered in ≤15 seconds via an autoinjector

Simple Dosing

  • Low volume—only 1.2 mL for everyone (fixed dose)
  • 3 injection-site options:
  •   abdomen
  •   thigh
  •   upper arm (caregiver administration only)

Get your patients started on ANDEMBRY today!

Download The Referral Form

Reference: 1. Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2023 Apr 15;401(10384):1266]. Lancet. 2023;401(10382): 1079-1090. doi:10.1016/S0140-6736(23)00350-1.